Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-349-1971
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable
Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions
What is Catabasis Pharmaceuticals' stock symbol?
Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."
When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?
Catabasis Pharmaceuticals shares reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Catabasis Pharmaceuticals' earnings last quarter?
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.93) by $0.08. View Catabasis Pharmaceuticals' Earnings History.
When is Catabasis Pharmaceuticals' next earnings date?
What price target have analysts set for CATB?
3 brokers have issued 12 month price targets for Catabasis Pharmaceuticals' shares. Their predictions range from $15.00 to $77.00. On average, they anticipate Catabasis Pharmaceuticals' stock price to reach $37.3333 in the next twelve months. This suggests a possible upside of 416.4% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.
What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.
Has Catabasis Pharmaceuticals been receiving favorable news coverage?
Headlines about CATB stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catabasis Pharmaceuticals earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Catabasis Pharmaceuticals' key competitors?
Some companies that are related to Catabasis Pharmaceuticals include Kezar Life Sciences (KZR), AC Immune (ACIU), Insys Therapeutics (INSY), Kindred Biosciences (KIN), American Brivision (Holding) (ABVC), Protagonist Therapeutics (PTGX), Geron (GERN), Syros Pharmaceuticals (SYRS), Verrica Pharmaceuticals (VRCA), Minerva Neurosciences (NERV), Aduro BioTech (ADRO), Constellation Pharmaceuticals (CNST), Merus (MRUS), Immune Design (IMDZ) and Lannett (LCI).
What other stocks do shareholders of Catabasis Pharmaceuticals own?
Who are Catabasis Pharmaceuticals' key executives?
Catabasis Pharmaceuticals' management team includes the folowing people:
- Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)
- Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)
- Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)
- Mr. Noah Clauser, VP of Fin. & Controller
- Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54)
When did Catabasis Pharmaceuticals IPO?
(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.
Who are Catabasis Pharmaceuticals' major shareholders?
Catabasis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Oppenheimer & Co. Inc. (0.66%), Stonepine Capital Management LLC (0.58%), Geode Capital Management LLC (0.41%), Geode Capital Management LLC (0.41%) and Northern Trust Corp (0.23%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.
Which institutional investors are selling Catabasis Pharmaceuticals stock?
How do I buy shares of Catabasis Pharmaceuticals?
Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catabasis Pharmaceuticals' stock price today?
One share of CATB stock can currently be purchased for approximately $7.23.
How big of a company is Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals has a market capitalization of $83.07 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-25,870,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis.
What is Catabasis Pharmaceuticals' official website?
How can I contact Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals' mailing address is One Kendall Square Bldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]
MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
